The enzymes market has seen considerable growth due to a variety of factors.
• Growth has been experienced rapidly in the enzymes market size over recent years. The market which was valued at $13.38 billion in 2024 is expected to rise up to $15.33 billion in 2025, representing a compound annual growth rate (CAGR) of 14.6%.
The notable growth during the historic period can be credited to the expansion and globalization of the market, as well as the investment in research and development. Factors such as consumer awareness and demand, advancements in bioprocessing technology, and the emphasis on waste reduction and recycling also contributed to the growth.
The enzymes market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for enzymes is projected to experience a swift expansion in the forthcoming years, reaching $25.88 billion in 2029 with a compound annual growth rate (CAGR) of 14.0%.
The expected growth during the forecast period can be credited to market demand dynamics, emphasis on sustainable practices, trends in health and nutrition, the biofuel and renewable energy sector, and emerging applications. The projection period is anticipated to see major trends such as advancements in biotechnology, an increase in demand for sustainability, a surge in demand from the food and beverage sector, expansion of industrial applications, and a rising consumer preference for natural products.
The growing incidences of digestive ailments are anticipated to stimulate the expansion of the enzyme market. Digestive complications represent a series of health issues that impinge on the digestive system. Typical digestive diseases include gastroesophageal reflux disease (GERD), cancer, irritable bowel syndrome (IBS), lactose intolerance, hiatal hernia, and gallstones. Digestive enzymes assist in decomposing food into tinier molecules that can be taken in by the body. For instance, as per the National Center for Biotechnology Information (NCBI), a US-based scientific research community resource, in October 2022, the incidence of irritable bowel syndrome (IBS) fluctuates between 10% and 15% in the United States, and about 12% of patients seek medical assistance in primary care practices as a response to IBS-related grievances. Therefore, the escalating incidences of digestive issues are propelling the enzyme market's growth.
The enzymes market covered in this report is segmented –
1) By Product Type: Asparaginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products
2) By Application: Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications
3) By End User: Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories
Subsegments:
1) By Asparaginase: L-asparaginase, Erwinia Asparaginase, Pegylated Asparaginase
2) By Lipase: Gastric Lipase, Pancreatic Lipase, Fungal Lipase, Bacterial Lipase
3) By Protease: Serine Proteases, Cysteine Proteases, Aspartic Proteases, Metalloproteases
4) By Nattokinase: Nattokinase Powder, Nattokinase Capsules
5) By Chitinase: Plant Chitinase, Microbial Chitinase
6) By Serratiopeptidase: Serratiopeptidase Tablets, Serratiopeptidase Capsules
7) By Collagenase: Type I Collagenase, Type II Collagenase, Type III Collagenase
8) By Ligase: DNA Ligase, RNA Ligase
9) By Other Products: Amylase, Cellulase, Beta-Glucanase, Other Specialty Enzymes
Leading businesses in the enzyme market are working on the creation of advanced products like Lamzede to provide improved treatment options for patients. Lamzede, also known as velmanase alfa, is a drug meant for alleviating alpha-mannosidosis, an uncommon genetic disorder triggered by the lacking action of the lysosomal alpha-galactosidase-A enzyme. For example, in May 2023, Chiesi Global Rare Diseases, a pharmaceutical production enterprise based in the US, secured FDA approval for Lamzede (velmanase alfa) to be used for treating non-neurological symptoms in patients diagnosed with mild-to-moderate alpha-mannosidosis. Lamzede, produced in Chinese hamster ovary (CHO) cells through recombinant DNA technology, is a recombinant variant of human alpha-mannosidase. It has gained recognition as the first enzyme replacement therapy sanctioned in the U.S. specifically for addressing non-central nervous system indications of alpha-mannosidosis.
Major companies operating in the enzymes market include:
• Novozymes A/S
• DuPont Industrial Biosciences
• BASF SE
• Koninklijke DSM N.V.
• Chr. Hansen Holding A/S
• Roche Holding AG
• Advanced Enzyme Technologies Ltd.
• AB Enzymes GmbH
• Codexis Inc.
• Dyadic International Inc.
• Amano Enzyme Inc.
• Adisseo France SAS
• Biocatalysts Ltd.
• Amano Enzyme Inc.
• Enzyme Development Corporation
• Creative Enzymes
• Hayashibara Co. Ltd.
• Thermo Fisher Scientific Inc.
• Associated British Foods Plc
• Lonza Group AG
• Novus International Inc.
• Epygen Biotech
• DSM Nutritional Products AG
• Soufflet Biotechnologies SAS
• Beijing Leili Marine Bioindustry Inc.
• Jiangsu Boli Bioproducts Co. Ltd.
North America was the largest region in the enzymes market in 2024. The regions covered in the enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.